References
- 김인섭. 2003. 바이러스 불활화 공정에 대한 hepatitis A virus와 murine encephalomyocarditis virus의 민감도 비교. 미생물학회지 39, 242-247
- Active Pharmaceutical Ingredients Committee. 1999. Cleaning validation in active pharmaceutical ingredient manufacturing plants
- Arnauld, C., O. Legecy, Y. Laurian, R. Thiery, M. Denis, P. Blanchard, and A. Jestin. 1998. Development of a PCR-based method coupled with a microplate colorimetric assay for the detection of porcine parvovirus and application to diagnosis in piglet tissues and human plasma. Mol. Cell. Probes 12, 407-416 https://doi.org/10.1006/mcpr.1998.0205
- Boschetti, N. and A. Johnston. 2005. Virus elimination and validation. Methods Mol. Biol. 308, 209-220
- Bronrson, K., J. Brown, E. Hamilton, and K.E. Stein. 2003. Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re-use. J. Chromatogr. A. 989, 155-163 https://doi.org/10.1016/S0021-9673(02)01697-7
- Burgoyne, R.F., M.C. Priest, K.L. Roche, and G. Vella. 1993. Systematic development and validation of sanitization protocols for a chromatography system designed for biotherapeutics purification. J. Pharm. Biomed. Anal. 11, 1317-1325 https://doi.org/10.1016/0731-7085(93)80118-K
- Celis, P. and G. Silvester. 2004. European regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products. Dev. Biol. 118, 3-10
- Cuthbertson, B., K.G. Reid, and P.R. Foster. 1991. Viral contamination of human plasma and procedures for preventing virus transmission by plasma products, p. 385-435. In J.R. Harris (ed.), Blood separation and plasma fractionation. Willey-Liss Inc., New York
- Darling, A. 2002. Validation of biopharmaceutical purification process for virus clearance evaluation. Mol. Biotechnol. 21, 57-83 https://doi.org/10.1385/MB:21:1:057
- Farshid, M. 2004. Viral safety evaluation of plasma-derived therapeutic products. Dev. Biol. 118, 11-15
- Food and Drug Administration. 1993. Guide to inspection for validation of cleaning processes
- Horaud, F. 1991. Introductory remark: viral safety of biologicals. Dev. Biol. Stand. 75, 3-7
- Horowitz, B. 1990. Blood protein derivative viral safety: observations and analysis. Yale J. Med. 63, 361-369
- Huang, C., J.-J. Hung, C.-Y. Wu, and M.-S. Chien. 2004. Multiplex PCR for rapid detection of pseudorabies virus, porcine parvovirus and porcine circoviruses. Vet. Microbiol. 101, 209-214 https://doi.org/10.1016/j.vetmic.2004.04.007
- International Conference on Harmonisation. 1998. Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability. Federal Resister 63, 51074-51084
- Jeong, H.-S., J,-H. Shin, Y.-N. Park, J.-Y. Choi, Y.-L. Kim, B.-G. Kim, S.-R. Ryu, S.-Y. Baek, S.-H. Lee, and S.-N. Park. 2003. Development of real-time RT-PCR for evaluation of JEV clearance during purification of HPV type 16 L1 virus-like particles. Biologicals 31, 223-229 https://doi.org/10.1016/S1045-1056(03)00064-2
- Kim, I.S., Y.W. Choi, S.R. Lee, H.S. Woo, and S. Lee. 2001. Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. Biotechnol. 11, 497-503
- Kim, I.S., Y.W. Choi, S.R. Lee, M.S. Lee, K.H. Huh, and S. Lee. 2001. Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. 39, 67-73
- Kim, I.S., Y.W. Choi, S.R. Lee, Y. Kang, K.M. Lee, D.H. Park, H.S. Woo, and S. Lee. 2002. Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7, 340-346 https://doi.org/10.1007/BF02933518
- Kim, J. and C. Chae. 2003. Multiplex nested PCR compared with in situ hybridization for the differentiation of porcine circoviruses and porcine parvovirus from pigs with postweaning multisystematic wasting syndrome. Can. J. Vet. Res. 67, 133-137
- Kim, J., D.U. Han, C. Choi, and C. Chae. 2003. Simultaneous detection and differentiation between porcine circovirus and porcine parvovirus in boar semen by multiplex seminested polymerase chain reaction. J. Vet. Med. Sci. 65, 741-744 https://doi.org/10.1292/jvms.65.741
- Kleinman, S. 1999. Residual risk of transfusion transmitted viral infections among seronegative donors: application of the incidence/ window period model. Dev. Biol. Stand. 102, 61-65
- Morrica, A., C. Nardini, A. Falbo, A. C. Bailey, and E. Bucci. 2003. Manufacturing process of Anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance. Biologicals 31, 1-9 https://doi.org/10.1016/S1045-1056(02)00067-2
- Mosley, J.W. and J. Rakela. 1999. Foundling viruses and transfusion medicine. Transfusion 39, 1041-1044 https://doi.org/10.1046/j.1537-2995.1999.39101041.x
- Parkman, P.D. 1996. Safety of biopharmaceuticals: a current perspective. Dev. Biol. Stand. 88, 5-7
- Prowse, C., C.A. Ludlam, and P.L. Yap. 1997. Human parvovirus B19 and blood products. Vox Sang. 72, 1-10 https://doi.org/10.1046/j.1423-0410.1997.00001.x
- Roberts, P. 1996. Virus safety of plasma products. Rev. Med. Virol. 6, 25-38 https://doi.org/10.1002/(SICI)1099-1654(199603)6:1<25::AID-RMV162>3.0.CO;2-2
- Saldanha, J. 2001. Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. J. Clin. Virol. 20, 7-13 https://doi.org/10.1016/S1386-6532(00)00149-9
- Schilt, U. 1989. Overview of viruses relevant to blood transfusion. Curr. Stud. Hematol. Blood Transf. 56, 1-8
- Sherwood, W.C. 1993. The significance of the blood-borne viruses: blood banking and transfusion medicine. Dev. Biol. Stand.81, 25-33
- Sofer, G. 2003. Current issues in validation of chromatography. Dev. Biol. 113, 61-64
- The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on plasma derived medicinal products (CPMP/BWP/269/95 rev2)
- Willkommen, H., I. Schmidt, and J. Lower. 1999. Safety issues for plasma derivatives and benefit from NAT testing. Biologicals 27, 325-331 https://doi.org/10.1006/biol.1999.0227